What Lagricel Ofteno Treats: Main Uses and Benefits

The core function of Lagricel Ofteno is applied across domains where additional symptomatic support is needed. The active ingredient is commonly used to help with burning and irritation due to dryness or exposure to wind and sun. The solution is relevant in contexts marked by increased discomfort or tension associated with ocular dryness.

It is commonly used to help with symptoms that interfere with daily functioning such as those associated with Dry Eye Disease, certain eye procedures, or irritation linked to environmental exposure. The drops are relevant for managing symptom clusters that may become intense, such as the persistent stinging and foreign body sensation, and are commonly used when short-term symptomatic assistance is needed.

This supportive action contributes to easing the overall symptom load and may assist with maintaining functional stability when symptoms are more noticeable. The product is applied in addressing symptoms related to physical discomfort, particularly those that create noticeable functional strain.

---

Quick Fact: Therapeutic Use

Therapeutic Focus	Symptom Focus	Benefit Focus
Conditions	Symptoms	Patient Benefit
Relevant in conditions characterized by periods of heightened symptoms (e.g., DED).	Helps address symptom clusters that may become intense, such as stinging and burning.	Supports general well-being during symptomatic phases by easing the overall symptom load.

Regulatory References

1. NIH DailyMed overview

Who Can and Cannot Use Lagricel Ofteno?

Population eligibility for Lagricel Ofteno (Sodium Hyaluronate Ophthalmic Solution) is officially defined by regulatory documents, focusing on established use and specific restrictions.

---

Contraindications and Restrictions

Population Group	Regulatory Status
Hypersensitivity	Contraindicated (absolute prohibition against use if allergic to Sodium Hyaluronate or any component).
Pediatric Patients (Under 18)	Not Recommended (Safety and effectiveness are not established; clinical experience is lacking).
Active Ocular Pathology	Conditional Use (Use is restricted in the presence of active infections, such as bacterial conjunctivitis, or healing disorders of the ocular surface).
Pregnant or Nursing Women	Conditional Use (Safety data from well-controlled human studies are not available; use only if clearly needed).

---

Established Use

Lagricel Ofteno is established and permitted for use in the Adult Population (18 years and older). Regulatory information indicates use is generally acceptable for the Older Adult Population, with no documented differences in safety or effectiveness when compared to younger adults. No specific explicit restrictions related to hepatic (liver) or renal (kidney) impairment are typically noted in the regulatory labeling for this topical ophthalmic solution.

The interaction profile for Lagricel Ofteno (Sodium Hyaluronate ophthalmic solution) is primarily defined by its topical administration and lack of systemic absorption. As the active ingredient is an endogenous polysaccharide that does not enter the bloodstream in clinically significant amounts, official regulatory documents state that the medicine is not involved in systemic pharmacokinetic interactions.

---

Absence of Systemic Interactions

Interaction Category	Regulatory Assessment
Metabolic/Transporter Interactions	None documented. The substance is not systemically metabolized.
Pharmacodynamic Interactions	None documented. No systemic additive or synergistic effects are officially described.
Contraindications	None documented. No drug, food, alcohol, or herbal product is formally classified as contraindicated for co-administration.

---

Administration-Timing Constraint

The only documented interaction constraint relates to the co-administration of other topical ophthalmic medicinal products. This is a physical administration-timing interaction to prevent the lubricant from interfering with the uptake or coverage of other eye medicines on the ocular surface. Official regulatory guidance mandates a required separation between applications.

The mandatory rule for co-administration states that the Sodium Hyaluronate solution must be applied before any other eye drop or eye ointment. A separation interval of 10 to 15 minutes must be observed between the application of this medicine and any subsequent topical eye product. This constraint is specific to the local ocular environment and does not involve systemic exposure.

The mechanism of Lagricel Ofteno is purely biophysical and surface-acting, driven by the specific properties of the Sodium Hyaluronate polymer. This agent provides a physical coating and engages cellular support mechanisms, rather than acting on classical pharmacological receptors.

The Viscoelastic Shielding Mechanism

This domain covers how the high molecular weight polymer creates a non-Newtonian viscoelastic film on the corneal and conjunctival epithelia. This mechanism of dynamic viscosity modulation is the basis for creating a continuous, low-friction shield , which results in the localized reduction of shear stress and mechanical trauma to the ocular surface during blinking.

Tear Film Stabilization via Mucoadhesion

This core mechanism involves the hygroscopic (water-binding) and mucoadhesive properties of Sodium Hyaluronate. By trapping moisture and adhering through physicochemical bonds to the eye's natural mucin layer, the polymer stabilizes the pre-corneal tear film structure. This action leads directly to an increase in Tear Film Break-up Time (BUT), sustaining the hydrated state and physical integrity of the surface barrier.

Support for Epithelial Repair Pathways

Beyond its mechanical role, the active ingredient engages a supportive signaling mechanism through interaction with the CD44 receptor on corneal epithelial cells. This localized interaction is associated with the modulation of cellular motility and proliferation, assisting in promoting re-epithelialization and establishing the functional integrity of the corneal barrier.

Administration of Lagricel Ofteno

Lagricel Ofteno is an ophthalmic solution designed for topical application to the eye. Proper administration is necessary to ensure the solution is distributed effectively across the ocular surface.

Application Technique

The application process generally involves the following steps to maintain the integrity of the solution and the comfort of the user:

• Preparation: Individuals typically wash their hands thoroughly with soap and water before handling the ophthalmic container.
• Positioning: Tilting the head back or lying down helps facilitate the placement of the drops. Looking upward while gently pulling the lower eyelid down creates a small pocket for the solution.
• Instillation: The container is held over the eye without allowing the dropper tip to touch the eye, eyelids, or any other surface. This prevents potential contamination of the remaining solution. One drop is usually released into the conjunctival sac (the space between the eye and the lower eyelid).
• Post-Application: After applying the drop, closing the eye gently for a brief period allows the solution to spread. Applying light pressure to the inner corner of the eye (near the nose) for one to two minutes may help keep the solution on the ocular surface.

Usage with Contact Lenses

Because Lagricel Ofteno is often used to manage symptoms associated with ocular dryness, its compatibility with contact lenses is a common consideration. Some formulations are preservative-free, which may influence how they interact with different types of lenses. Users generally consult specific product labeling regarding whether lenses should be removed prior to use or if the solution can be applied while wearing them.

Handling and Storage

To maintain the quality of the ophthalmic solution, the container must be capped tightly immediately after use. Storing the product at the temperature specified on the packaging is necessary to ensure the stability of the active ingredients. If the solution changes color or becomes cloudy, it is typically discarded.

Recent Clinical Evidence

Research has explored the use of Lagricel Ofteno in the management of ocular conditions, focusing primarily on dry eye disease (DED) and supporting corneal healing following surgical procedures. These investigations contribute to the understanding of the product's profile within the category of ocular lubricants containing sodium hyaluronate.

Efficacy Studies in Dry Eye Disease

Completed Phase IV clinical studies have assessed Lagricel Ofteno (containing Sodium Hyaluronate 0.4%) in patients diagnosed with mild to moderate dry eye disease. One non-inferiority, controlled, multicenter study compared its efficacy against other sodium hyaluronate-based ophthalmic solutions over a 30-day period. The primary outcome measure in this trial was the change in the Ocular Surface Disease Index (OSDI) score, a patient-reported measure of symptom severity and visual function related to DED.

Corneal Re-epithelialization Research

Other Phase IV research has evaluated the product in the context of corneal re-epithelialization following photorefractive keratectomy (PRK) surgery. This randomized, controlled, comparative study specifically examined the time required for the corneal surface to heal, comparing the product to another commercial tear substitute. These trials enroll adult patients who meet strict preoperative and postoperative criteria, excluding those with pre-existing conditions like dry eye, glaucoma, or previous ocular inflammation.

Safety and Tolerability

Studies consistently include the incidence of adverse events as a key secondary outcome. Adverse events, defined as any unfavorable reaction observed during the investigation, are monitored throughout the treatment period to assess the product's safety and tolerability profile in the studied populations.

Key Studies & References

1. Prospective, randomized, multi-center study comparing 0.4% sodium hyaluronate with 0.1% sodium hyaluronate in the treatment of mild to moderate dry eye disease.

Common questions about Lagricel Ofteno (FAQ)

Q: What should I do if I miss a dose?

If a dose of Lagricel Ofteno is forgotten, official guidance suggests applying it as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose is typically skipped, and the regular dosing schedule is resumed. Official information indicates that two doses should not be used at the same time to compensate for a missed dose.

---

Q: Are there any warnings for use in children or during pregnancy?

Regulatory documents indicate that safety and effectiveness have not been established for use in pediatric patients (under 18 years of age), meaning clinical experience is lacking. For pregnant or nursing women, official product information advises that the product should be used only if clearly needed, as safety data from controlled human studies are not available for these populations.

---

Q: What is the correct procedure for instilling the drops?

General guidance for administering eye drops emphasizes strict aseptic handling, which includes washing hands thoroughly before use. The procedure typically involves tilting the head back, gently pulling down the lower lid, and administering the drop. To maintain the sterility of the remaining solution, it is crucial not to let the dropper tip contact the eye, eyelid, or any other surface.

---

Q: Is it safe to drive after using Lagricel Ofteno?

The possible side effects for Lagricel Ofteno include transient blurring of vision, which may occur immediately following instillation. Official safety information recommends waiting until vision is completely clear before engaging in activities that require sharp sight, such as driving or operating machinery.

---

Q: Why do I have to wait 10-15 minutes before using another eye product?

The mandatory waiting period of 10 to 15 minutes is a physical administration-timing constraint mandated by official regulatory guidance. This rule ensures that the viscoelastic film created by Lagricel Ofteno does not physically interfere with or block the proper absorption or coverage of any subsequent topical eye medicine that is applied.

---

Q: How long after opening should I discard the multi-dose bottle?

Multi-dose containers should be discarded after a set period following the first opening, even if solution remains. This discard period is typically intended to prevent contamination and is often 90 days, or sometimes less. The specific expiration time frame is provided in the product's official instructions from the manufacturer.

---

Q: Does Lagricel Ofteno require a prescription?

The regulatory status of Lagricel Ofteno—whether it is prescription-only or available over-the-counter—can vary based on the specific country and jurisdiction. While this type of ocular lubricant is widely accessible, the specific classification of the product can be confirmed by reviewing local regulatory labeling or consulting with a pharmacist.

---

Q: Can I reuse the single-dose vials if there is solution left?

No, single-dose units are specifically designed for a single application and must be discarded immediately after use. This is because these units typically do not contain preservatives, and storing or reusing them significantly compromises the product's sterility, which carries a high risk of bacterial contamination.

---

Q: What should I do if I accidentally swallow the eye drops?

In the event of accidental ingestion, contacting a local poison control center or seeking emergency medical attention is the typical recommended course of action. This information is consistent with general drug safety guidance.

How to Store and Dispose of Lagricel Ofteno?

Lagricel Ofteno (Sodium Hyaluronate ophthalmic solution) must be stored at controlled room temperature, typically defined as 15 C to 30 C (59 F to 86 F). It is a mandatory requirement to keep the product from freezing and to avoid exposure to excessive heat or direct sunlight.

For multi-dose containers, the cap must be kept tightly closed when not in use. Single-dose units must be discarded immediately after one use to prevent contamination and maintain sterility; they should not be reused or stored.

As with all medications, Lagricel Ofteno must be stored out of the sight and reach of children.

Disposal of any unused or expired solution must follow local pharmaceutical waste regulations. The product should not be disposed of in household trash or wastewater unless specifically permitted by a local drug take-back program.